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Background: Homologous recombination repair (HRR) pathway deficiencies have significant implications for cancer
predisposition and treatment strategies. Improved quantitative methods for functionally characterizing these
deficiencies are required to accurately identify patients at risk of developing cancer and to identify mechanisms of
drug resistance or sensitivity.
Methods: Flow cytometry-based single cell network profiling (SCNP) was used to measure drug-induced activation
of DNA damage response (DDR) proteins in cell lines with defined HRR pathway mutations (including ATM-/-,
ATM+/-, BRCA1+/-, BRCA2-/-) and in primary acute myeloid leukemia (AML) samples. Both non-homologous end
joining (NHEJ) and HRR pathways were examined by measuring changes in intracellular readouts (including p-H2AX,
p-ATM, p-DNA-PKcs, p-53BP1, p-RPA2/32, p-BRCA1, p-p53, and p21) in response to exposure to mechanistically distinct
genotoxins. The cell cycle S/G2/M phase CyclinA2 marker was used to normalize for proliferation rates.
Results: Etoposide induced proliferation-independent DNA damage and activation of multiple DDR proteins in primary
AML cells and ATM +/+but not ATM -/- cell lines. Treatment with the PARPi AZD2281 +/- temozolomide induced DNA
damage in CyclinA2+ cells in both primary AML cells and cell lines and distngiushed cell lines deficient (BRCA2-/-) or
impaired (BRCA1+/-) in HRR activity from BRCA1+/+ cell lines based on p-H2AX induction. Application of this assay to
primary AML samples identified heterogeneous patterns of repair activity including muted or proficient activation of
NHEJ and HRR pathways and predominant activation of NHEJ in a subset of samples.
Conclusions: SCNP identified functional DDR readouts in both NHEJ and HRR pathways, which can be applied to
identify cells with BRCA1+/- haploinsuffiency and characterize differential DDR pathway functionality in primary clinical
samples.
Keywords: Genomic instability, DNA damage repair, Cell cycle, Homologous recombination, Non-homologous end
joining, BRCA, ATM, PARP, Multiparameter flow cytometry, FACSBackground
The DNA damage response (DDR), through the action of
sensors, transducers and effectors, orchestrates the appro-
priate recognition of DNA damage and the repair and
resolution of stalled DNA replication [1]. This process is
coordinated through complex interplay between cell cycle,
apoptosis, and cell survival signaling. The two major* Correspondence: rachael.hawtin@Nodality.com
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homologous recombination repair and non-homologous
end joining (HRR and NHEJ, respectively, Figure 1) [1].
HRR predominates in replicating cells and is less error
prone, using the identical homologous sister chromatid as
a sequence template to repair DSB [2]. HRR is also
involved in the repair of interstrand DNA cross-links
(ICL) in conjunction with the Fanconi anemia pathway
[3]. NHEJ is the predominantly active pathway in resting
cells and is the more error-prone mechanism, actingtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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Figure 1 Overview of measured DDR pathways with focus on repair of DSB. Experimentally measured parameters are shown in light red.
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template [2,4].
Impaired cellular capacity to repair DNA damage has
significant clinical implications, including the develop-
ment of cancer and the response of cancer cells to cyto-
toxic therapies [3]. Previous studies have used mutagen
sensitivity, host cell reactivation or comet assays to de-
monstrate associations between functional DNA repair
capacity and cancer status or clinical response to chemo-
therapy or radiation. These data are, however, limited in
clinical applicability due to lack of standardization and
poor interlaboratory reproducibility [3]. The ability to
reproducibly quantify the functional capacity of a cell to
repair DNA DSB would enable the identification of indi-
viduals at risk of developing cancer and may aid in the
selection of appropriate therapeutics for cancer patients.
Single cell network profiling (SCNP) using multipara-
metric flow cytometry has emerged as versatile tool to
quantitatively study the function of multiple specific bio-
logical pathways and signaling networks simultaneously
using standardized methods and instrumentation [5,6].
By characterizing cellular signaling responses at the
single cell level following exposure to extracellular
modulators, signaling network integrity and dysfunction
can be revealed to identify properties not detectable inresting cells or in the average of the total cell population.
Using this functional assay, it is possible to quantitatively
measure DNA damage (p-H2AX) in primary clinical sam-
ples, such as newly diagnosed adult AML [7]. Herein,
SCNP was applied to establish reproducible tools to meas-
ure, at the level of the single cell, the functionality of HRR
and NHEJ repair pathways with the ultimate goal of iden-
tifying functional impairment or deficiency in DNA repair




This manuscript describes the results of multi-parametric
flow cytometry experiments measuring drug-induced
DNA damage and activation of multiple DDR readouts in
the HRR and NHEJ DSB repair pathways in distinct cell
subsets defined based on cell cycle phase to quantify the
functional integrity of the cellular DNA repair pathways.
Cell lines with functional or defective DNA repair capaci-
ties were used to identify reagents capable of detecting ac-
tivation of DNA damage repair pathways. To confirm that
these methods are capable of identifying functional hap-
ploinsufficency in a model of BRCA1 inherited germline
mutation, cell lines of known HRR status (BRCA1+/- and
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were used to demonstrate the ability to quantify activation
of these pathways in primary cancer cells.
Flow sample and specimen description
Cell lines
Individual cell lines harboring mutations in ATM, BRCA2
or BRCA1 were used in the study. Following the suppliers’
instructions, cell lines obtained from ATCC (Manassas,
VA) were maintained in RPMI-1640 supplemented with
10% FCS, and cell lines obtained from Coriell Cell
Repositories (Camden, New Jersey) were maintained in
complete RPMI-1640 supplemented with 15% FCS.
Cell line panel 1 was used to establish tools for measur-
ing ATM-dependent DNA damage responses; ATM wild
type cell lines [U937 and RS4;11 (ATCC), GM00536 and
GM09703 (Coriell)], were compared with an ATM +/- cell
line [GM03323 (Coriell)] and two ATM-/- cell lines
[GM01526 and GM03189 (Coriell)] for measurement of
etoposide-induced DDR readouts (details in SCNP assay
section below).
Cell line panel 2 was used to detect differences between
BRCA2-/-, BRCA1+/-, and BRCA1+/+ samples in response
to PARPi treatment (details in SCNP assay section below).
To model BRCA2-/- status, an Epstein Barr Virus (EBV)-
transformed B lymphocblast cell line [GM13023 (Coriell)]
from a Fanconi’s Anemia patient with homozygous
BRCA2/FANCD1 mutation was used. To model heterozy-
gous BRCA1 mutation (BRCA1 +/-), 5 EBV-transformed B
lymphoblast cell lines [HCC1937BL (ATCC), GM14091,
GM13705, GM13709 and GM14090 (Coriell)] from pa-
tients with BRCA1-mutated familial breast cancer were
used. Similarly, to model wild type BRCA1 (BRCA1 +/+)
status, 5 EBV-transformed B lymphoblast cell lines
[(HCC1954BL (ATCC), GM00536, GM005423, GM17230
and GM17217 (Coriell)] from breast cancer patients whose
tumors are negative for BRCA1 mutations or from healthy
donors were evaluated.
Patient samples
AML samples consisted of either peripheral blood mo-
nonuclear cell (PBMC) or bone marrow mononuclear
cell (BMMC) specimens obtained from pediatric or adult
patients with AML. Mononuclear cells were purified by
ficoll centrifugation then cryopreserved in 90% FBS, 10%
DMSO. In accordance with the Declaration of Helsinki,
all patients consented to the collection of biospecimens
for biology studies.
Sample processing and instrument details
SCNP assay
SCNP assays were performed as described previously [8].
Aliquots of cryopreserved cells were thawed at 37°C,
washed, resuspended in RPMI-1640 medium supplementedwith 60% fetal bovine serum (FBS), and live mononuclear
cells isolated via ficoll density gradient. After a second
washing step with RPMI-1640 60% FBS, cells were washed
in RPMI-1640 10% FBS, counted, filtered, re-suspended in
RPMI-1640 10% FBS, then aliquoted (100,000 cells/con-
dition for primary AML cells or 50,000 cells/condition
for cell lines) and rested for 30 minutes at 37°C before
addition of therapeutic agents (each tested at a clinically
relevant dose ranging between Cmax and trough level as
reported in pharmacokinetic studies [9-11]). For all condi-
tions, following incubation with drugs, cells were stained
with amine aqua viability dye (Life Technologies, Carlsbad,
CA) to distinguish non-viable cells, fixed with 1.6% para-
formaldehyde for 10 minutes at 37°C, pelleted, perme-
abilized with 100% ice-cold methanol, and stored at -80°C.
For antibody staining, cells were washed with FACS buffer
(PBS, 0.5% BSA, 0.05% NaN3), pelleted, and stained with
unlabeled antibody cocktails followed by fluorochrome
conjugated goat anti mouse or goat anti rabbit secondary
antibodies (Life Technologies and Jackson Immunore-
search, West Grove, PA), then blocked with normal rabbit
serum and normal mouse serum (Life Technologies) and
stained with cockails of fluorochrome-conjugated anti-
bodies. Cocktails included antibodies against cell surface
markers for cell gating of AML cells [e.g. CD45, CD11b
(Beckman Coulter, Brea, CA), CD34 and CD33 (BD Bio-
sciences, San Jose, CA)] and up to 3 antibodies against
intracellular signaling molecules (detailed below) for 6- 8-
color flow cytometry assays.
Data was acquired on an LSR II flow cytometer using
the FACS DIVA software (BD Biosciences). All flow
cytometry data were analyzed with FlowJo (TreeStar
Software, Ashland, OR) or WinList (Verity House Software,
Topsham, ME). Daily QC of the LSRII cytometers was
performed as previously described [12]. Dead cells and
debris were excluded by forward and side scatter proper-
ties combined with amine aqua viability dye exclusion. For
AML samples, “all” non-apoptotic leukemic cells were
identified based on expression of CD45 and side-scatter
properties and lack of the apoptosis marker cleaved PARP
(cPARP, BD Biosciences) as previously described [8,13],
while CyclinA2 (Beckman Coulter) staining discriminated
CyclinA2- and CyclinA2+ subsets. Similarly, normal lym-
phocytes within AML samples were identified by low side
scatter and high CD45 expression as previously described
[8,13]. For cell lines, forward scatter, side scatter, amine
aqua, and cleaved PARP similarly identified live non-
apoptotic (healthy) cells and CyclinA2 staining discrimi-
nated CyclinA2- and CyclinA2+ subsets. Specific drug
treatments and readouts examined were as follows:
a) For experiments measuring multiple DDR readouts
after etoposide treatment, cell lines (Cell line panel 1) or
primary AML samples were treated with 30 μg/mL eto-
poside (Sigma, St. Louis, MO) for 2 h or 6 h and assayed
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(T2609) (Biolegend, San Diego, CA), p-53BP1 (S1778),
p-ATM (S1981), p-p53 (S15), p-Chk2 (T68), and p-H2AX
(S139) (Cell Signaling Technologies, Danvers, MA).
b) For experiments showing magnitude and reproduci-
bility of multiple AZD2281+/- temozolomide-induced
DDR readouts and the ability of these readouts to stratify
for HRR status, BRCA1 +/+ , BRCA1 +/- , and BRCA2 -/-
cell lines (Cell line panel 2) were treated with 6 μg/mL
AZD2281 (Selleck, Houston, TX) +/- 2 μg/mL temozolo-
mide (Sigma) for 48-72 h and assayed for p-H2AX (S139),
p-RPA2/32 (T21) (Abcam, Cambridge, MA), p-DNA-
PKcs (T2609), p21, p-ATM (S1981) and p-BRCA1 (S1423)
in CyclinA2- and CylcinA2+ cells. In these experiments a
2 μg/mL dose of temozolomide was used due to excessive
apoptosis observed with the combination of AZD2281
with higher doses of temozolomide (10 μg/mL) at later
timepoints (data not shown).
c) For experiments measuring the cell cycle selectivity of
individual genotoxic agents, cell lines in culture or AML
samples pre-treated for 48 h with a panel of myeloid
growth factors to induce proliferation in all AML subtypes
[20 ng/mL of IL-3 (BD Biosciences), TPO, SCF (R&D
Systems, Minneapolis, MN) and FLT3L (ebiosciences,Figure 2 Illustration of metrics used to quantify DDR responses. Two
responses to modulation. The magnitude of the cellular responses is measu
responding is measured by the (B) Uu metric. (B) Examples of signaling re
signaling will yield Uu values > 0.5; Lack of intracellular cellular response to
result in large magnitude shifts and a maximum Uu value of 1.0; Robust de
Uu value of 0.0.San Diego, CA)] were challenged for 6 h with etoposide
(30 μg/mL), PARP inhibitor AZD2281 (6 μg/mL), temo-
zolomide (10 μg/mL), or the combination of AZD2281 +
temozolomide (6 μg/mL + 10 μg/mL) and assessed for in-
duced p-H2AX in distinct subsets of cells including
CyclinA2+ cells, CyclinA2- cells, or “All” live, cPARP-
cells regardless of CyclinA2 status.
Data analysis details
Metrics
Metrics, illustrated in Figure 2, for quantifying DDR (Log2-
Fold and Uu) were applied to gated cell populations con-
taining at least 200 events and have been described
previously [8,14]. Briefly, the Log2Fold metric measures
the magnitude of the responsiveness of a cell population
to modulation where a value of zero indicates lack of
induced signaling while a positive value indicates an in-
crease in the signaling response of a population. The “Uu”
metric measures the proportion of responsive cells by
comparing the overlap and rank-order of the modulated
and unmodulated populations on a cell-by-cell basis and
ranges from zero to one where 0.5 indicates no change,
values >0.5 indicate cells have increased in signal, and
values < 0.5 indicate that cells have decreased in signal vs.classes of metrics are calculated to measure distinct biological
red using (A) the Log2Fold metric while the fraction of cells
sponses for different Uu values are shown. Top to Bottom: Induced
modulation will yield Uu values ~ 0.5; Robust increases in signaling
creases in signaling result in large magnitude shifts with a minimum
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comparing data on a normalized scale of zero to one and
was used here to compare DDR readouts in AML samples
and to assess the cell cycle selectivity of various drugs by
comparing the proportion of responding cells within
CyclinA2- or CyclinA2+ populations for each agent. Popu-
lation frequency metrics for the percentage of healthy
non-apoptotic (Aqua-, cPARP-) cell line or leukemic cells
were calculated. For both cell lines and AML samples, per-
centages of CyclinA2- or CyclinA2+ cells of the parent
population were calculated. For both cell lines and AML
samples DDR metrics were calculated for “all” healthy
non-apoptotic cells as well as CyclinA2- and CyclinA2+
subsets where possible.
Statistics
Individual DDR readouts were correlated against each
other using Pearson’s linear correlation.
Data on drug-induced cytotoxicity and DNA damage
were correlated with proliferation levels using Pearson’s
linear correlation. Comparison of CyclinA2+ vs CyclinA2-
cells for magnitude and CV of signaling was performed
with using a paired student’s t-test. Student’s t-test was
performed to compare BRCA1+/- vs. BRCA1+/+ cell line
responses.
Results
Development of SCNP assays to quanitfy induction of
DNA damage and ATM mediated activation of DNA
damage repair pathways
To quantitatively assess induction of DNA damage and
activation of DDR pathways at the single cell level, re-
agents and experimental conditions were first optimized
to detect the induction of activation motifs within the
two major double strand break repair pathways: NHEJ
and HRR. Using the topoisomerase II inhibitor etoposide
to induce DDR pathway activation and DNA damage, re-
agents recognizing the induced phosphorylation sites on
multiple proteins within the NHEJ and HRR pathways
were examined (Figure 1). In a panel of cell lines con-
taining defined mutations including ATM-/-, ATM+/-,
and ATM+/+ genotypes (Cell line panel 1), etoposide in-
duced phosphorylation and activation of all proteins
tested. DDR response data for each ATM genotype and
an illustration of the gating scheme used are shown in
Figure 3. Consistent with the functional role of ATM in
mediating signaling through both HRR and NHEJ path-
ways, etopside treatment induced lower activation of all
readouts in the ATM-/- cell lines compared to ATM+/-
and ATM+/+ cell lines and showed slightly lower activa-
tion of the ATM+/- cell line vs. ATM+/+cell lines for
two readouts (p-ATM and p-DNA-PKcs). Of note, no
significant differences were seen comparing the percen-
tages of live, healthy cells or CyclinA2+ cells betweenATM-/- , ATM+/- and ATM+/+ genotypes (data not
shown), suggesting that DDR pathway measurements may
be more informative than general measures of cell death/
cell cycle status. This supports the utility of the evaluated
DDR readouts (nodes) to quantify ATM mediated activa-
tion of DNA damage response pathways.
Quantification of PARPi +/- TMZ induced p-H2AX levels in
CyclinA2+ cells robustly identifies alterations in HRR
pathway activity
The ability of SCNP to measure DDR responses in cellular
subpopulations was next exploited as a method to quan-
tify the activity of cell cycle specific DDR pathways such
as HRR. To identify robust DDR readouts which could be
leveraged to recognize cells with functionally defective or
impaired HRR pathway activity, the cellular response to
PARPi AZD2281 was examined using an expanded panel
of DDR readouts and cell lines with known mutations in
HRR machinery, including BRCA2-/-, BRCA1+/-, and
BRCA1+/+ lines (Cell line panel 2). Cells were treated
with PARPi (AZD) +/- temozolomide (TMZ) for 48-72 h
and analyzed for the induction of 6 DDR proteins
[p-H2AX, p-RPA2, p-DNAPKcs, p-ATM, p-BRCA1 and
p21 (total protein)] in all cells (regardless of CyclinA2
expression), in CyclinA2- and in CyclinA2+ cell subsets
within the same cell line. This choice of conditions was
based on previous experiments in cell lines demonstrating
that PARPi AZD2281 +/- temozolomide selectively in-
duced DSBs (p-H2AX) in CyclinA2+ cells while etoposide
induces DSBs (p-H2AX) in both CyclinA2- and CyclinA2+
cells (data not shown).
PARPi-induced DDR responses from all cells, CyclinA2-,
and CyclinA2+ subsets were examined in the HRR mutant
and proficient cell lines in the context of their HRR status.
Elevated levels of PARPi-induced p-ATM, p-BRCA1,
p-RPA2, and p-DNA-PKcs were detected in the BRCA2-/-
cell line in CyclinA2+ cells at both 48 h and 72 h (Figure 4).
BRCA1+/- vs BRCA1+/+ cell lines were not distinguished
by readouts for PARPi +/- TMZ-induced p21, p-ATM,
p-BRCA1, p-RPA2, and p-DNA-PKcs in any population
analyzed (Table 1). Although some BRCA1+/- samples
demonstrated a trend of higher PARPi-induced p21 levels
vs. BRCA1+/+ samples (Figure 4), the difference was not
significant (Table 1).
The most sensitive readout for HRR pathway function
was p-H2AX. Analysis of CyclinA2+ cells consistently
demonstrated highest induced p-H2AX levels in the
homozygous BRCA2-/- cell line, intermediate p-H2AX
levels in heterozygous BRCA1+/- cell lines, and lowest
p-H2AX levels in BRCA1+/+ cell lines (Figure 5). Im-
portantly, gating on CyclinA2+ cells distinguished
BRCA1+/- from BRCA1+/+ lines; p-H2AX levels were
significantly (p < .05) higher in BRCA1+/- lines com-
pared to BRCA1+/+ lines in CyclinA2+ cells but not in
Figure 3 Analysis of etoposide inducible SCNP DDR readouts in cell lines with characterized DDR pathway deficiencies. (A) Flow plots
illustrate the gating scheme to identify live (Aqua-) non-apoptotic, healthy (cPARP-) cells for analysis of DDR responses. (B) Flow plot examples of
p-DNA-PKcs, p-H2AX, p-ATM and p-BRCA1 induction in ATM+/+, ATM+/- and ATM-/- cell lines (Red: 2 h unstimulated, Blue: 2 h etoposide treated,
(30 μg/mL)). (C) Shown are Log2Fold change in levels of intracellular readouts following 2 hr etoposide treatment. DDR readouts: p-ATM, p-BRCA1,
p-DNA-PKcs, p-53BP1, p-p53, p-Chk2, and p-H2AX. Cell lines (Cell line panel 1, Materials and methods) are coded by color. ATM-/- cell lines (grey and
back dots) consistently show lower induced values for all modulated DDR readouts measured. In contrast, ATM +/- cells (magenta dots) shows slightly
lower DDR readouts vs. ATM +/+ cells for some (p-ATM, p-DNA-PKcs) but not all reaoduts in these conditions.
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points and treatment conditions tested (Figure 5, Table 1).
These data suggest that analysis of DDR readouts spe-
cifically in CyclinA2+ cells enables more accurate quan-
tification of HRR proficiency, possibly by reducing (and
normalizing for) the confounding effects of different pro-
liferation rates across samples.
To further examine CyclinA2 gating as a method to con-
trol for proliferation rate, the above PARPi-induced DDR
data from BRCA2-/-, BRCA1+/-, and BRCA1 +/+ cell lines
were evaluated for the percentage of CyclinA2+ cells as a
measure of proliferation for each cell line and used to
compute correlations between proliferation and PARPi +/-
temozolomide-induced DDR readouts measured in three
populations: a) CyclinA2+ cells only, b) CyclinA2- cells
only or b) all healthy cells. While DDR readouts measured
in all live cells or CyclinA2- cells demonstrated higher
correlations with proliferation (average R2 values: 0.403,0.505, respectively), DDR readouts from CyclinA2+ sub-
sets were less correlated with proliferation (average
R2: 0.194). These data confirm that analysis of DDR
readouts specifically in CyclinA2+ cells helps normalize
for cell proliferation rate, enabling more accurate quantifi-
cation of HRR proficiency. In addition, examination of the
percentages of live, healthy cells with or without PARPi
treatment demonstrated no significant differences in apop-
tosis between BRCA1+/+ and BRCA1+/- samples (data
not shown), which is consistent with published literature
[15,16], and suggests that DDR pathway measurements
may be more sensitive than apoptosis measurements in
identifying altered DNA repair phenotypes.
To further understand the technical components of
quantifying PARPi-induced DDR readouts in CyclinA2-
or CyclinA2+ cells, the magnitude and reproducibility of
DDR readouts were directly compared between CyclinA2-
and CyclinA2+ subsets.
Figure 4 Analysis of PARPi-induced DDR in cell lines shows higher induction of multiple readouts in BRCA2-/- cells compared to
BRCA1+/- and BRCA1+/+cells. (A) 48 or 72 hr (columns) PARPi AZD2281 (AZD, 6 μg/mL)-induced Log2Fold values for DDR readouts p-RPA2,
p-DNA-PKcs, p21, p-ATM, and p-BRCA1 (rows) are shown for CyclinA2- or CyclinA2+ subsets (columns) of tested cell lines. Values shown are mean
averages from 2 independent experiments. Cell lines are coded by HRR status (BRCA1+/+, squares; BRCA1+/-, circles; BRCA2-/-, crosses). (B) Flow plot
examples of p-RPA2, p-DNA-PKcs, p-ATM induction in BRCA1+/+, BRCA1+/-, and BRCA2-/- cell lines at 48 h (Red: Unstimulated, Blue: AZD2281).
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(AZD) +/- TMZ-induced DDR responses were statistically
higher for all 6 DDR readouts in CyclinA2+ vs. CyclinA2-
cells (paired t-test p-values directly comparing CyclinA2-
and CyclinA2+ data ranged from p = 1.28 × 10-4 to
p = 8.86 × 10-9). Within the CyclinA2+ population,
p-H2AX and p21 showed highest induction of signalTable 1 T-Test P-values comparing DDR readouts between BR
Treatment AZD AZD














p-H2AX 0.536 0.119 0.012 0.558 0.151 0.
p-RPA2 0.545 0.372 0.545 0.599 0.442 0
p-DNA-PKcs 0.398 0.419 0.957 0.597 0.469 0
p21 0.315 0.413 0.132 0.645 0.737 0
p-ATM 0.636 0.848 0.390 0.940 0.693 0
p-BRCA1 0.754 0.954 0.608 0.505 0.872 0
Statistically significant p-values (p < .05) for stratifying BRCA1+/- vs. BRCA1+/+cell linamong the DDR readouts. Higher levels of DDR readouts
were observed in conditions with temozolomide in both
CyclinA2- and CyclinA2+ cells.
To assess the reproducibility of these data, the coeffi-
cient of variation (CV) between two independent experi-
ments was computed. As shown in Figure 6B, better
reproducibility was observed for all 6 DDR readouts inCA1+/- vs. BRCA1+/+ cell lines
AZD + TMZ AZD + TMZ















039 0.673 0.172 0.014 0.509 0.272 0.011
.229 0.875 0.445 0.916 0.900 0.767 0.859
.336 0.776 0.952 0.894 0.758 0.562 0.297
.203 0.693 0.708 0.364 0.778 0.706 0.452
.228 0.746 0.967 0.736 0.813 0.920 0.694
.721 0.858 0.839 0.756 0.684 0.970 0.860
es are shown in bold.
Figure 5 Analysis of PARPi-induced p-H2AX in CyclinA2- and CyclinA2+ subsets in DDR wild type or mutant cell lines distinguishes
distinct levels of HRR deficiency including haploinsufficiency. (A) Flow plot examples of p-H2AX vs. CyclinA2 in untreated or 48 h PARPi AZD2281
(6 μg/mL) treated BRCA1+/+, BRCA1+/- and BRCA2-/- cell lines. (B) PARPi AZD2281 +/- temozolomide (2 μg/mL)-induced p-H2AX in CyclinA2- or CyclinA2+
subsets (columns) after treatment for 48 or 72 hr (rows) for cell lines of known HRR status (BRCA1+/+, squares; BRCA1+/-, circles; BRCA2-/-, crosses; Cell line
panel 2, Materials and methods). Mean average Log2Fold values from two independent experiments are shown. T-test p-valuescomparing BRCA1+/+and
BRCA1+/- cell lines are shown for each condition with significant (p < .05) indicated by an asterisk (*). Analysis of AZD2281 +/- temozolomide treatment
in CyclinA2+ cells demonstrates highest p-H2AX induction in the BRCA2-/- cell line, medium induction in BRCA1+/- cell lines and lowest induction in
BRCA1+/+ cell lines.
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age CV: 0.252) in all treatment conditions (+/- TMZ),
with significant differences (p < .05 paired t-test) in CVs
observed between CyclinA2+ and CyclinA2- populations
for 11/12 conditions tested. Of note, these CVs are simi-
lar to values observed with comparable quantitiative flow
cytometery bio-assays such as induction and detection
of intracellular cytokines (average CV from manual
gating: 0.28) [17].
Assessment of DNA damage and activation of DNA
damage repair pathways in primary AML samples
To test the ability of SCNP to measure cell-cycle specific
DDR responses to specific genotoxic agents in primary
samples, peripheral blood or bone marrow samples from
patients with AML were stimulated to proliferate by
48 h incubation with a panel of myeloid growth factorsthen evaluated for p-H2AX induction after 6 h in vitro
treatment with etoposide, PARPi, TMZ, or the com-
bination of PARPi + TMZ. As expected, growth factor
treatment stimulated AML cells to enter the cell cycle as
measured by the frequency of CyclinA2+ cells (Figures 7
and 8). Of note, the frequency of CyclinA2+ cells after
growth factor treatment was similar among AML sam-
ples (median: 25.0%, standard deviation: 8.0%). Similar
to results seen with cell lines (data not shown), treat-
ment of primary AML samples with etoposide resulted
in decreased numbers of CyclinA2+ cells available for
analysis and induced DNA damage (p-H2AX) in both
CyclinA2- and CyclinA2+ AML cell subsets (Figure 7).
In contrast, treatment of primary AML samples with
TMZ, PARPi, or the combination of PARPi + TMZ-
induced proliferation-dependent DNA damage (p-H2AX)
selectively in CyclinA2+ AML cells, again consistent with
Figure 6 (See legend on next page.)
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Figure 6 Analysis of magnitude and reproducibility of PARPi-induced DDR readouts in CyclinA2+ vs CyclinA2- cells. (A). DDR wild type
or mutant EBV cell lines (ATRp-/-, BRCA2-/-, BRCA1+/-, BRCA1+/+ genotypes, Cell Line panel 2, Materials and methods) were treated with PARP
inhibitor AZD2281 (AZD, 6 μg/mL) or the combination of AZD2281 + temozolomide (AZD + TMZ, 6 μg/mL + 2 μg/mL, respectively) (columns) for
48 hr and assayed for activation of DDR readouts. Shown are Log2Fold values measuring the magnitude of modulation of p-H2AX, p-RPA2, p-DNA-PKcs
(left) or p21, p-ATM, p-BRCA1 (right) in both CyclinA2- and CyclinA2+ subsets (top). Tabulated below are the average Log2Fold (L2F) values for each
readout and treatment condition in CyclinA2- and CyclinA2+ subsets, with the paired t-test p-value comparing CyclinA2- and CyclinA2+ L2F values.
Data shown are the average of two experiments (B). Shown are Coefficient of Variation (CV) values measuring the reproducibility between the two
experiments shown in (A). CVs were computed for CyclinA2- and CyclinA2+ populations for each readout and treatment condition. Tabulated below are
the average CVs for each readout and treatment condition in CyclinA2- and CyclinA2+ subsets and the paired t-test p-value comparing CyclinA2- and
CyclinA2+ CVs.
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plots for four additional AML samples are shown in
Figure 8 and an illustration of of gating for leukemic or
lymphocyte cell subsets is shown in Figure 9. Interestingly,
analysis of the lymphocyte cell responses from AMLFigure 7 Analysis of DDR in CyclinA2+ and CyclinA2- cells demonstra
samples. Primary AML (PBMC and BMMC) samples were treated with etop
(10 μg/mL), or the combination of AZD2281 + temozolomide (6 μg/mL + 1
leukemic cells of a representative AML sample. (B) Shown is the proportion
allows comparisons of induced DDR from different drugs on a normalized
leukemic cell population (All cells) or in CyclinA2- or CyclinA2+ subsets. Tab
population.samples demonstrated that; 1) as expected lymphocytes
did not respond to the myeloid growth factors and lacked
CyclinA2 expression and; 2) in agreement with the results
from analysis of gated AML cells, etoposide induced a ro-
bust p-H2AX response in CyclinA2- lymphocytes whiletes cell-cycle specific effects of individual genotoxins in AML
oside (30 μg/mL), PARP inhibitor AZD2281 (6 μg/mL), temozolomide
0 μg/mL) for 6 hr. (A) Example flow plots of CyclinA2 vs. p-H2AX for all
of cells (Uu metric) with induced p-H2AX in each sample; this metric
scale. Modulated signaling through p-H2AX was measured in the bulk
ulated below are the average values of all AML samples in each
Figure 8 Genotoxin effects on CyclinA2 subets of leukemic cells or lymphocytes from myeloid growth factor stimulated AML samples.
Shown are flow plot examples of CyclinA2 vs. p-H2AX for leukemic AML cells (left) or normal lympohcytes (right) gated (see Materials and methods) from
5 AML samples treated with etoposide (30 μg/mL), PARP inhibitor AZD2281 (6 μg/mL), temozolomide (10 μg/mL), or the combination of AZD2281 +
temozolomide (6 μg/mL + 10 μg/mL) for 6 hr. While leukemic CyclinA2+ cells show induced p-H2AX from all agents tested, leukemic and lymphocytic
CyclinA2- cells only demonstrate induced p-H2AX after etoposide treatment.
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mal effects on CyclinA2- lymphocytes (Figure 8).
A larger panel of markers was then examined in the
context of primary AML, measuring both NHEJ and HRR
pathway activity in response to in vitro etoposide treat-
ment for 2 h or 6 h. As etoposide and other genotoxic
agents are currently part of standard AML chemotherapy
regimens [18,19], examination of etoposide-induced DDR
readouts in AML samples may be clinically relevant. As
etoposide treatment was previously seen to have robust
effects in CyclinA2- cells without a specific requirement
for proliferation, these experiments were conducted on
freshly thawed AML samples without growth factor pre-
incubation. As expected at both 2 h and 6 h post-thaw,
AML samples displayed low percentages of CyclinA2+
cells (2 h average: 3.41%, 6 h average: 3.8%) and good
post-thaw viability with live, non-apoptotic leukemic cell
frequencies averaging 57.2% and 58.0% at 2 h and 6 h in
unstimulated conditions. Treatment with etoposide for
2 h or 6 h had no effect on the percentages of non-
apoptotic cells (data not shown). Induction of each DDR
readout was examined in response to etoposide treatment
to assess the integrity of signaling along the DDR path-
ways, and the inter-relationships between signaling path-
ways. Flow plots illustrating the gating scheme used and
examples of etoposide responses in AML samples are
shown in Figure 9. At both 2 h and 6 h co-activation of re-
pair proteins within unique DDR pathways was observedfollowing etoposide treatment (Figure 9). Stronger correla-
tions were observed for readouts within a single pathway
(HRR pathway: p-ATM vs. p-BRCA1) than for readouts
from distinct pathways (HRR pathway: p-BRCA1 vs. NHEJ
pathway: p-DNA-PKcs). Comparison of NHEJ (p-DNA-PK)
with HRR (p-BRCA1) readouts in individual samples
(top right panel) identified AML samples with lower
activation of both repair pathways, samples with robust
activation of both pathways, and others which predomi-
nately activate NHEJ, suggesting that individual leukemia
samples vary in the magnitude of activation of specific
DSB repair pathways (Figure 9).Discussion
Genomic instability is a hallmark of cancer. Quantitative
functional analysis of genomic instability could signifi-
cantly improve risk assessment for cancer development
in healthy individuals and characterize the DNA repair
capacity of established cancers as a method for deter-
mining individualized therapeutic strategy. In order to
achieve this, a more comprehensive, functional un-
derstanding of DNA repair pathways and the ability to
quantify these pathways in samples from individual pa-
tients is needed. Moreover, functionally profiling DNA
damage and repair pathways induced or targeted by spe-
cific agents will enable mechanistic characterization and
differentiation of distinct drug classes [20,21].
Figure 9 Analysis of correlations between etoposide-induced DDR nodes in AML samples highlights unique patient biology. Primary
AML (PBMC and BMMC) samples were treated with 30 μg/ml etoposide for 2 hr or 6 hr and the modulation of a panel of DDR readouts was measured
(p-53BP1, p-ATM, p-BRCA1, p-DNA-PKcs, p-H2AX). (A) Flow plots illustrating the gating scheme for leukemic cells and lymphocytes from AML samples
(left) and etoposide induced DDR responses in leukemic cells for p-H2AX, p-DNA-PKcs, p-p53, p-ATM, p-53BP1, p-Chk2 and p-BRCA1 (right). (B) Individual
modulated DDR readouts were then compared to each other with bivariate plots, with R2 values shown. While higher correlations were
observed between the DSB response (p-ATM) and HRR pathways (p-BRCA1) (left scatter plot), and between measures of DNA damage (p-H2AX) and
NHEJ repair (p-DNA-PKcs) (middle scatter plot), lower correlations were observed across pathways comparing HRR (p-BRCA1) and NHEJ (p-DNA-PKcs)
readouts (right scatter plot). Samples enclosed by a red circle demonstrate relatively higher activation of NHEJ pathway components (p-DNA-PKcs) as
compared to HRR pathway components (p-BRCA1). (C) Correlation R2 values between etoposide induced DDR readouts at 2 h and 6 h.
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damage-inducing therapeutics is potentially affected by
the accumulation of multiple individual mutations in
distinct components comprising DNA damage repair
pathways. Functional assays, such as SCNP, can uniquely
enable quantification of the physiological consequences
of these alterations, which converge at the level of path-
way and network responses. As such, SCNP can simul-
taneously highlight both the mechanisms of action for
specific drugs as well as characterize the DNA repair
capacity of samples from individual patients. This ap-
proach may complement sequencing-based mutational
analysis of DNA repair genes, such as BRCA1/2 sequen-
cing, where many mutations have unknown function,
epigenetic and/or non-coding alterations may not bedetected, and the combined effects of pathway mutations
are not known or understood [22].
By applying SCNP to simultaneously measure DNA
damage and activation of multiple DDR pathways in dis-
tinct cell cycle subsets, and by using cell lines with known
mutations in DDR signaling, data from the current study
support the following major conclusions: First, while the
ability to measure p-H2AX, p-ATM, p-Chk2 and p-DNA-
PKcs using flow cytometry is well established [7,23-28],
these data provide examples of methods to measure activa-
tion of additional DNA repair proteins from repair path-
ways including NHEJ (p-53BP1) and HRR (p-RPA2,
p-BRCA1) using flow cytometry. Second, by controlling
for proliferation rate through a focused SCNP analysis of
CyclinA2+ cells, these data demonstrate the ability to
Rosen et al. Journal of Translational Medicine 2014, 12:184 Page 13 of 14
http://www.translational-medicine.com/content/12/1/184functionally identify and differentiate cells with partially
impaired (BRCA1+/-) or completely defective (BRCA2-/-)
HRR repair machinery. For future studies, It is possible
that this ability to control for proliferative state could be
further improved by the use of additional markers beyond
CyclinA2 such as CyclinE to mark G1 cells or p-Histone
H3 to mark cells in M phase cells. Third, these data de-
monstrate that primary AML samples quantifiably differ in
their relative activation of HRR vs. NHEJ components.
This ability to differentiate unique AML signatures based
on DDR pathway activation may have therapeutic implica-
tions; additional studies using clinically annotated samples
to enable correlation with patient clinical responses to spe-
cific agents are planned.
The experiments described in this analysis were per-
formed on cryopreserved AML samples. High concor-
dances between both cell health and functional responses
comparing fresh vs. cryopreserved AML samples have
previously been established [29], supporting the potential
utility of the current assay for the analysis of freshly iso-
lated samples. Studies to confirm this are planned.
These findings are consistent with pre-clinical data
showing that PARP inhibition for the treatment of can-
cers is most effective in BRCA-deficient or mutant sam-
ples. The absence of a functional HRR pathway forces
the cell to use the error-prone NHEJ repair of DNA
damage, which ultimately results in the accumulation of
misrepaired DNA, complex DNA rearrangements and
cell death [15,30-33]. Importantly, PARP inhibitor sensi-
tivity has also been associated with lower expression
of genes for additional DNA damage repair proteins
beyond BRCA1 [34], further supporting the need to
holistically examine the functionality of the entire DNA
repair network in order to accurately identify cellular
competence for repair of DNA damage.
Another recently described method for assessing HRR
function in single cells, which has generated useful data in
cell lines, measures repair and reactivation of an HRR sub-
strate reporter gene (DR-GFP) [35]. However, the require-
ment for transient transfection in this system challenges
the potential clinical utility of this approach [3]. Assays
measuring RAD51 foci by microscopy have also been de-
scribed as a measure of HRR function and our data sug-
gest that these assays could be improved by specifically
analyzing RAD51 foci in CyclinA2+ cells. SCNP, in
contrast to these techniques, enables the simultaneous
analysis in primary cells of multiple DDR signaling nodes
in multiple cell subsets, providing a signature of the func-
tional consequences of genetic mutations, without the
need for any cell manipulation or subset isolation.
These data illustrate the capability to quantifiably mea-
sure functional activation of the 2 major DNA DSB
repair pathways, NHEJ and HRR, both of which are rele-
vant to genotoxin responses and cancer predisposition.As mutations in additional DNA repair pathways [such
as nucleotide excision repair (NER), base excision repair
(BER), and mismatch repair (MMR)] are also associated
with cancer predisposition and/or drug sensitivity [3],
the future development of functional assays for these
additional repair pathways is also clinically relevant. The
cell line data presented here establish that DNA repair
deficiencies, including HRR haploinsufficiency, are de-
tectable and quantifiable through functional assays, a
notion recently supported by independent data [36]. Ex-
periments using PBMC samples from healthy donors or
patients with known germline mutations in the HRR
pathway are needed to validate the clinical utility of
these functional assays. Such analyses could form the
basis for the development of screening tests to identify
subjects at higher risk of developing cancer or stratifica-
tion tests to inform on cancer patient selection for treat-
ment with specific agents, such as PARP inhibitors.
This study demonstrates the utility of SCNP to func-
tionally quantify multiple DNA damage-associated read-
outs in single cells of distinct cell cycle subsets and
identify samples with defective DNA DSB repair capacity,
including inherited haploinsufficiency. As multivariate
analyses of SCNP data have proven useful in the predic-
tion of clinical outcome in other oncology settings [37,38],
future experiments with larger numbers of clinical sam-
ples are warranted in order to capitalize on the multidi-
mensional nature of these data.
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